GSK's Arexvy provides protection over three RSV seasons, trial shows
GSK
1,339.50p
12:54 24/12/24
GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
FTSE 100
8,136.99
12:59 24/12/24
FTSE 350
4,491.87
12:54 24/12/24
FTSE All-Share
4,449.61
13:14 24/12/24
Pharmaceuticals & Biotechnology
20,055.90
12:54 24/12/24
Tony Wood, chief scientific officer at the pharma giant, said the company was "excited" by the data from the AReSVi-006 trial, which evaluated the efficacy of Arexvy against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older.
"This is the only RSV vaccine with efficacy and safety data available through three full seasons," Woods said in a statement on Tuesday.
The results showed that after a single dose of Arexvy, cumulative efficacy over three full RSV seasons was clinically meaningful at 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD, when compared with a placebo. In the third season, the vaccine's efficacy was 48.0% against RSV-LRTD.
"We will continue to provide data on longer term follow-up to help recommending bodies determine future revaccination schedules," Woods said.
GSK's stock, which was trading in the red in line with the market before the announcement, held on to losses despite the positive news. Share were down 1.6% at 1,456p by 1303 BST.